Figure 1.
Therapeutic Efficacy of Intratumoral NDV Is Dependent on Adaptive Immunity
(A) Treatment scheme. Tumors were established by implantation of 1 × 105 (B–F) or 2 × 105 B16-F10 cells in the right flank. (B) Representative luminescence images from animals treated with NDV-fluc. (C) Quantification of average luminescence from the tumor sites at the indicated time points. Left, average luminescence. Right, area under curve (AUC) calculated from the curves on the left. (D) Individual tumor growth curves. (E) Average tumor volumes followed until first death in each treatment group. Indicated statistical comparisons were performed using t test using the average tumor volumes on the last day of measurement before the first death. (F) Overall survival with CD4 or CD8 depletion. (G) Individual tumor growth curves with NK cell depletion. (H) Average tumor volumes followed until first death in each treatment group. (I) Overall survival with NK depletion. Data in (A)–(F) and (G)–(I) each represent one of two independent experiments with n = 5–10 per group. Mean ± SEM is shown. ns, not significant; *p < 0.05; ****p < 0.0001.